{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:58:39Z","timestamp":1792277919987,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009060","name":"Sidaction","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) are promising molecules for therapeutic or prophylactic interventions. Beyond neutralization, bNAbs exert Fc-dependent functions including antibody-dependent cellular cytotoxicity and activation of the complement. Here, we show that a subset of bNAbs targeting the CD4 binding site and the V1\/V2 or V3 loops inhibit viral release from infected cells. We combined immunofluorescence, scanning electron microscopy, transmission electron microscopy and immunogold staining to reveal that some bNAbs form large aggregates of virions at the surface of infected cells. This activity correlates with the capacity of bNAbs to bind to Env at the cell surface and to neutralize cell-free viral particles. We further show that antibody bivalency is required for viral retention, and that aggregated virions are neutralized. We have thus identified an additional antiviral activity of bNAbs, which block HIV-1 release by tethering viral particles at the surface of infected cells.<\/jats:p>","DOI":"10.1038\/s41467-022-28307-7","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T11:06:03Z","timestamp":1643799963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-1378","authenticated-orcid":false,"given":"J\u00e9r\u00e9my","family":"Dufloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Planchais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Fr\u00e9mont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-1585","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Lorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Guivel-Benhassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9686-9194","authenticated-orcid":false,"given":"Karl","family":"Stefic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Casartelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-1398","authenticated-orcid":false,"given":"Arnaud","family":"Echard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9131-3341","authenticated-orcid":false,"given":"Philippe","family":"Roingeard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Mouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-1475","authenticated-orcid":false,"given":"Olivier","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3952-4261","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Bruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"28307_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.it.2014.08.007","volume":"35","author":"H Mouquet","year":"2014","unstructured":"Mouquet, H. Antibody B cell responses in HIV-1 infection. Trends Immunol. 35, 549\u2013561 (2014).","journal-title":"Trends Immunol."},{"key":"28307_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nature12746","volume":"503","author":"M Shingai","year":"2013","unstructured":"Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277 (2013).","journal-title":"Nature"},{"key":"28307_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature12744","volume":"503","author":"DH Barouch","year":"2013","unstructured":"Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224 (2013).","journal-title":"Nature"},{"key":"28307_CR4","doi-asserted-by":"publisher","first-page":"eaaf1483","DOI":"10.1126\/scitranslmed.aaf1483","volume":"9","author":"MS Parsons","year":"2017","unstructured":"Parsons, M. S. et al. Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Sci. Transl. Med. 9, eaaf1483 (2017).","journal-title":"Sci. Transl. Med."},{"key":"28307_CR5","doi-asserted-by":"publisher","first-page":"18921","DOI":"10.1073\/pnas.1214785109","volume":"109","author":"B Moldt","year":"2012","unstructured":"Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl Acad. Sci. USA 109, 18921\u201318925 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28307_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature17677","volume":"533","author":"R Gautam","year":"2016","unstructured":"Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105 (2016).","journal-title":"Nature"},{"key":"28307_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","volume":"158","author":"A Halper-Stromberg","year":"2014","unstructured":"Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized Mice. Cell 158, 989\u2013999 (2014).","journal-title":"Cell"},{"key":"28307_CR8","doi-asserted-by":"publisher","first-page":"e1009339","DOI":"10.1371\/journal.ppat.1009339","volume":"17","author":"DC Hsu","year":"2021","unstructured":"Hsu, D. C. et al. TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. PLoS Pathog. 17, e1009339 (2021).","journal-title":"PLoS Pathog."},{"key":"28307_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","volume":"25","author":"M Caskey","year":"2019","unstructured":"Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat. Med. 25, 547\u2013553 (2019).","journal-title":"Nat. Med."},{"key":"28307_CR10","doi-asserted-by":"publisher","first-page":"101475","DOI":"10.1016\/j.smim.2021.101475","volume":"51","author":"B Julg","year":"2021","unstructured":"Julg, B. & Barouch, D. Broadly neutralizing antibodies for HIV-1 prevention and therapy. Semin. Immunol. 51, 101475 (2021).","journal-title":"Semin. Immunol."},{"key":"28307_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487 (2015).","journal-title":"Nature"},{"key":"28307_CR12","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206\u2013319ra206 (2015).","journal-title":"Sci. Transl. Med."},{"key":"28307_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"28307_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid, J. F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556 (2016).","journal-title":"Nature"},{"key":"28307_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"28307_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10844","volume":"7","author":"T Bruel","year":"2016","unstructured":"Bruel, T. et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat. Commun. 7, 10844 (2016).","journal-title":"Nat. Commun."},{"key":"28307_CR17","doi-asserted-by":"publisher","first-page":"10648","DOI":"10.1128\/JVI.01911-15","volume":"89","author":"B von Bredow","year":"2015","unstructured":"von Bredow, B. et al. Envelope glycoprotein internalization protects human and simian immunodeficiency virus-infected cells from antibody-dependent cell-mediated cytotoxicity. J. Virol. 89, 10648\u201310655 (2015).","journal-title":"J. Virol."},{"key":"28307_CR18","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1128\/JVI.03230-13","volume":"88","author":"M Veillette","year":"2014","unstructured":"Veillette, M. et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J. Virol. 88, 2633\u20132644 (2014).","journal-title":"J. Virol."},{"key":"28307_CR19","doi-asserted-by":"publisher","first-page":"e02325","DOI":"10.1128\/JVI.02325-16","volume":"91","author":"T Musich","year":"2017","unstructured":"Musich, T. et al. Monoclonal antibodies specific for the V2, V3, CD4-binding site, and gp41 of HIV-1 mediate phagocytosis in a dose-dependent manner. J. Virol. 91, e02325\u201316 (2017).","journal-title":"J. Virol."},{"key":"28307_CR20","doi-asserted-by":"crossref","first-page":"e49351","DOI":"10.15252\/embr.201949351","volume":"21","author":"J Dufloo","year":"2019","unstructured":"Dufloo, J. et al. Anti\u2010HIV\u20101 antibodies trigger non\u2010lytic complement deposition on infected cells. Embo Rep. 21, e49351 (2019).","journal-title":"Embo Rep."},{"key":"28307_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature06106","volume":"449","author":"AJ Hessell","year":"2007","unstructured":"Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101\u2013104 (2007).","journal-title":"Nature"},{"key":"28307_CR22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","volume":"158","author":"S Bournazos","year":"2014","unstructured":"Bournazos, S. et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158, 1243\u20131253 (2014).","journal-title":"Cell"},{"key":"28307_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1172\/JCI122466","volume":"129","author":"MS Parsons","year":"2018","unstructured":"Parsons, M. S. et al. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. J. Clin. Invest. 129, 182\u2013191 (2018).","journal-title":"J. Clin. Invest."},{"key":"28307_CR24","doi-asserted-by":"publisher","first-page":"eabe3349","DOI":"10.1126\/scitranslmed.abe3349","volume":"13","author":"L Hangartner","year":"2021","unstructured":"Hangartner, L. et al. Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates. Sci. Transl. Med. 13, eabe3349 (2021).","journal-title":"Sci. Transl. Med."},{"key":"28307_CR25","doi-asserted-by":"publisher","first-page":"18754","DOI":"10.1073\/pnas.2008236117","volume":"117","author":"M Asokan","year":"2020","unstructured":"Asokan, M. et al. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc. Natl Acad. Sci. USA 117, 18754\u201318763 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28307_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.chom.2018.07.018","volume":"24","author":"J Jin","year":"2018","unstructured":"Jin, J. et al. Neutralizing antibodies inhibit chikungunya virus budding at the plasma membrane. Cell Host Microbe 24, 417\u2013428.e5 (2018).","journal-title":"Cell Host Microbe"},{"key":"28307_CR27","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.celrep.2015.11.043","volume":"13","author":"J Jin","year":"2015","unstructured":"Jin, J. et al. Neutralizing monoclonal antibodies block chikungunya virus entry and release by targeting an epitope critical to viral pathogenesis. Cell Rep. 13, 2553\u20132564 (2015).","journal-title":"Cell Rep."},{"key":"28307_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04704-9","volume":"9","author":"S Bangaru","year":"2018","unstructured":"Bangaru, S. et al. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat. Commun. 9, 2669 (2018).","journal-title":"Nat. Commun."},{"key":"28307_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bbrc.2016.09.052","volume":"479","author":"S Teimoori","year":"2016","unstructured":"Teimoori, S. et al. Human transbodies to VP40 inhibit cellular egress of Ebola virus-like particles. Biochem. Bioph. Res. Co. 479, 245\u2013252 (2016).","journal-title":"Biochem. Bioph. Res. Co."},{"key":"28307_CR30","doi-asserted-by":"publisher","first-page":"13467","DOI":"10.1128\/JVI.01896-12","volume":"86","author":"M Kajihara","year":"2012","unstructured":"Kajihara, M. et al. Inhibition of marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J. Virol. 86, 13467\u201313474 (2012).","journal-title":"J. Virol."},{"key":"28307_CR31","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/v12050548","volume":"12","author":"RE Murphy","year":"2020","unstructured":"Murphy, R. E. & Saad, J. S. The interplay between HIV-1 Gag binding to the plasma membrane and Env incorporation. Viruses 12, 548 (2020).","journal-title":"Viruses"},{"key":"28307_CR32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrmicro3490","volume":"13","author":"EO Freed","year":"2015","unstructured":"Freed, E. O. HIV-1 assembly, release and maturation. Nat. Rev. Microbiol. 13, 484\u2013496 (2015).","journal-title":"Nat. Rev. Microbiol"},{"key":"28307_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46\u201361 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"28307_CR34","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell. Science. 343, 1260\u20131263 (2014).","journal-title":"Science"},{"key":"28307_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.tim.2017.10.007","volume":"26","author":"J Richard","year":"2018","unstructured":"Richard, J., Pr\u00e9vost, J., Alsahafi, N., Ding, S. & Finzi, A. Impact of HIV-1 envelope conformation on ADCC responses. Trends Microbiol. 26, 253\u2013265 (2018).","journal-title":"Trends Microbiol."},{"key":"28307_CR36","doi-asserted-by":"publisher","first-page":"e02440","DOI":"10.1128\/JVI.02440-16","volume":"91","author":"T Bruel","year":"2017","unstructured":"Bruel, T. et al. Lack of ADCC breadth of human nonneutralizing Anti-HIV-1 antibodies. J. Virol. 91, e02440\u201316 (2017).","journal-title":"J. Virol."},{"key":"28307_CR37","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1128\/JVI.00347-16","volume":"90","author":"B von Bredow","year":"2016","unstructured":"von Bredow, B. et al. Comparison of antibody-dependent cell-mediated cytotoxicity and virus neutralization by HIV-1 Env-specific monoclonal antibodies. J. Virol. 90, 6127\u20136139 (2016).","journal-title":"J. Virol."},{"key":"28307_CR38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nature06553","volume":"451","author":"SJD Neil","year":"2008","unstructured":"Neil, S. J. D., Zang, T. & Bieniasz, P. D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425\u2013430 (2008).","journal-title":"Nature"},{"key":"28307_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.chom.2008.03.001","volume":"3","author":"NV Damme","year":"2008","unstructured":"Damme, N. V. et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral vpu protein. Cell Host Microbe 3, 245\u2013252 (2008).","journal-title":"Cell Host Microbe"},{"key":"28307_CR40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.chom.2012.10.007","volume":"12","author":"RP Gal\u00e3o","year":"2012","unstructured":"Gal\u00e3o, R. P., Le Tortorec, A., Pickering, S., Kueck, T. & Neil, S. J. D. Innate sensing of HIV-1 assembly by tetherin induces NF\u03baB-dependent proinflammatory responses. Cell Host Microbe 12, 633\u2013644 (2012).","journal-title":"Cell Host Microbe"},{"key":"28307_CR41","doi-asserted-by":"crossref","unstructured":"Anand, S. P. et al. Antibody-induced internalization of HIV-1 Env proteins limits surface expression of the closed conformation of Env. J. Virol. 93, e00293-19 (2019).","DOI":"10.1128\/JVI.00293-19"},{"key":"28307_CR42","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1084\/jem.20131244","volume":"210","author":"M Malbec","year":"2013","unstructured":"Malbec, M. et al. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J. Exp. Med. 210, 2813\u20132821 (2013).","journal-title":"J. Exp. Med."},{"key":"28307_CR43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nature06998","volume":"454","author":"N Jouvenet","year":"2008","unstructured":"Jouvenet, N., Bieniasz, P. D. & Simon, S. M. Imaging the biogenesis of individual HIV-1 virions in live cells. Nature 454, 236\u2013240 (2008).","journal-title":"Nature"},{"key":"28307_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.tim.2013.05.001","volume":"21","author":"J Tan","year":"2013","unstructured":"Tan, J. & Sattentau, Q. J. The HIV-1-containing macrophage compartment: a perfect cellular niche? Trends Microbiol. 21, 405\u2013412 (2013).","journal-title":"Trends Microbiol."},{"key":"28307_CR45","doi-asserted-by":"publisher","first-page":"e1004751","DOI":"10.1371\/journal.ppat.1004751","volume":"11","author":"H Akiyama","year":"2015","unstructured":"Akiyama, H., Ramirez, N.-G. P., Gudheti, M. V. & Gummuluru, S. CD169-mediated trafficking of HIV to plasma membrane invaginations in dendritic cells attenuates efficacy of anti-gp120 broadly neutralizing antibodies. PLoS Pathog. 11, e1004751 (2015).","journal-title":"PLoS Pathog."},{"key":"28307_CR46","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1128\/JVI.05915-11","volume":"86","author":"H Koppensteiner","year":"2012","unstructured":"Koppensteiner, H., Banning, C., Schneider, C., Hohenberg, H. & Schindler, M. Macrophage internal HIV-1 is protected from neutralizing antibodies. J. Virol. 86, 2826\u20132836 (2012).","journal-title":"J. Virol."},{"key":"28307_CR47","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559\u2013563 (2017).","journal-title":"Nature"},{"key":"28307_CR48","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/nm.2233","volume":"16","author":"CT Ng","year":"2010","unstructured":"Ng, C. T. et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 16, 1117\u20131119 (2010).","journal-title":"Nat. Med"},{"key":"28307_CR49","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.aaf0972","volume":"352","author":"T Schoofs","year":"2016","unstructured":"Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997\u20131001 (2016).","journal-title":"Science"},{"key":"28307_CR50","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/COH.0000000000000555","volume":"14","author":"M Naranjo-Gomez","year":"2019","unstructured":"Naranjo-Gomez, M. & Pelegrin, M. Vaccinal effect of HIV-1 antibody therapy. Curr. Opin. Hiv. Aids 14, 325\u2013333 (2019).","journal-title":"Curr. Opin. Hiv. Aids"},{"key":"28307_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-014-0078-8","volume":"11","author":"DJ Stieh","year":"2014","unstructured":"Stieh, D. J. et al. Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology 11, 78 (2014).","journal-title":"Retrovirology"},{"key":"28307_CR52","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1089\/aid.2015.0050","volume":"31","author":"MR Alexander","year":"2015","unstructured":"Alexander, M. R., Sanders, R. W., Moore, J. P. & Klasse, P. J. Short communication: virion aggregation by neutralizing and nonneutralizing antibodies to the HIV-1 envelope glycoprotein. Aids Res. Hum. Retrov. 31, 1160\u20131165 (2015).","journal-title":"Aids Res. Hum. Retrov."},{"key":"28307_CR53","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1128\/JVI.00790-13","volume":"87","author":"NH Roy","year":"2013","unstructured":"Roy, N. H., Chan, J., Lambel\u00e9, M. & Thali, M. Clustering and mobility of HIV-1 Env at viral assembly sites predict its propensity to induce cell-cell fusion. J. Virol. 87, 7516\u20137525 (2013).","journal-title":"J. Virol."},{"key":"28307_CR54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jim.2015.04.010","volume":"422","author":"V Lorin","year":"2015","unstructured":"Lorin, V. & Mouquet, H. Efficient generation of human IgA monoclonal antibodies. J. Immunol. Methods 422, 102\u2013110 (2015).","journal-title":"J. Immunol. Methods"},{"key":"28307_CR55","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1126\/science.abb8008","volume":"369","author":"A Kumar","year":"2020","unstructured":"Kumar, A., Planchais, C., Fronzes, R., Mouquet, H. & Reyes, N. Binding mechanisms of therapeutic antibodies to human CD20. Science 369, 793\u2013799 (2020).","journal-title":"Science"},{"key":"28307_CR56","doi-asserted-by":"publisher","first-page":"e1008151","DOI":"10.1371\/journal.ppat.1008151","volume":"16","author":"RMVd Sluis","year":"2020","unstructured":"Sluis, R. M. V.d. et al. Diverse effects of interferon alpha on the establishment and reversal of HIV latency. PLoS Pathog. 16, e1008151 (2020).","journal-title":"PLoS Pathog."},{"key":"28307_CR57","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.1086907","volume":"301","author":"H Wardemann","year":"2003","unstructured":"Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374\u20131377 (2003).","journal-title":"Science"},{"key":"28307_CR58","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1126\/science.1207227","volume":"333","author":"JF Scheid","year":"2011","unstructured":"Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633\u20131637 (2011).","journal-title":"Science"},{"key":"28307_CR59","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","volume":"45","author":"J Huang","year":"2016","unstructured":"Huang, J. et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45, 1108\u20131121 (2016).","journal-title":"Immunity"},{"key":"28307_CR60","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856\u2013861 (2010).","journal-title":"Science"},{"key":"28307_CR61","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature12053","volume":"496","author":"H-X Liao","year":"2013","unstructured":"Liao, H.-X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469\u2013476 (2013).","journal-title":"Nature"},{"key":"28307_CR62","doi-asserted-by":"publisher","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","volume":"109","author":"H Mouquet","year":"2012","unstructured":"Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA 109, E3268\u2013E3277 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28307_CR63","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature10373","volume":"477","author":"LM Walker","year":"2011","unstructured":"Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466\u2013470 (2011).","journal-title":"Nature"},{"key":"28307_CR64","doi-asserted-by":"publisher","first-page":"17624","DOI":"10.1073\/pnas.1415789111","volume":"111","author":"D Sok","year":"2014","unstructured":"Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl Acad. Sci. USA 111, 17624\u201317629 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28307_CR65","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.1178746","volume":"326","author":"LM Walker","year":"2009","unstructured":"Walker, L. M. et al. Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target. Science 326, 285\u2013289 (2009).","journal-title":"Science"},{"key":"28307_CR66","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1128\/JVI.05312-11","volume":"85","author":"Z Zhu","year":"2011","unstructured":"Zhu, Z. et al. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-Like antibodies. J. Virol. 85, 11401\u201311408 (2011).","journal-title":"J. Virol."},{"key":"28307_CR67","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature11544","volume":"491","author":"J Huang","year":"2012","unstructured":"Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406\u2013412 (2012).","journal-title":"Nature"},{"key":"28307_CR68","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1089\/aid.1994.10.359","volume":"10","author":"A Buchacher","year":"1994","unstructured":"Buchacher, A. et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and epstein-barr virus transformation for peripheral blood lymphocyte immortalization. Aids Res. Hum. Retrov. 10, 359\u2013369 (1994).","journal-title":"Aids Res. Hum. Retrov."},{"key":"28307_CR69","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1084\/jem.20120423","volume":"209","author":"F Klein","year":"2012","unstructured":"Klein, F. et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 209, 1469\u20131479 (2012).","journal-title":"J. Exp. Med."},{"key":"28307_CR70","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nature07930","volume":"458","author":"JF Scheid","year":"2009","unstructured":"Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636\u2013640 (2009).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28307-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T20:05:31Z","timestamp":1700165131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28307-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["28307"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-28307-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"9 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"630"}}